Analysts' ratings for Beam Therapeutics (NASDAQ:BEAM) over the last quarter vary from bullish to bearish, as provided by 10 analysts.

In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $51.0, along with a high estimate of $80.00 and a low estimate of $25.00. A 7.07% drop is evident in the current average compared to the previous average price target of $54.88.

Diving into Analyst Ratings: An In-Depth Exploration

The standing of Beam Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

For valuable insights into Beam Therapeutics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.

Stay up to date on Beam Therapeutics analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Unveiling the Story Behind Beam Therapeutics

A Deep Dive into Beam Therapeutics's Financials

Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.

Decline in Revenue: Over the 3M period, Beam Therapeutics faced challenges, resulting in a decline of approximately -90.49% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Beam Therapeutics's net margin is impressive, surpassing industry averages. With a net margin of -300.51%, the company demonstrates strong profitability and effective cost management.

Return on Equity (ROE): Beam Therapeutics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -11.85%, the company showcases efficient use of equity capital and strong financial health.

Return on Assets (ROA): Beam Therapeutics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -7.94%, the company may face hurdles in achieving optimal financial returns.

Debt Management: Beam Therapeutics's debt-to-equity ratio is below the industry average at 0.22, reflecting a lower dependency on debt financing and a more conservative financial approach.

The Basics of Analyst Ratings

Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

Which Stocks Are Analysts Recommending Now?

Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.

This article was generated by Benzinga's automated content engine and reviewed by an editor.